SMARCA4 and neoplasm: Importantly, co-administration of both compounds had a significant synergistic effect on suppressing tumor growth leading to stable disease in the H1299 xenograft model during 21 days of treatment, suggesting that low dose IACS-010759 and potentially other OXPHOS inhibitors in combination with KD025 could be viable treatment options for SMARCA4-mutant lung cancers.